Inflammatory priming enhances mesenchymal stromal cell secretome potential as a clinical product for regenerative medicine approaches through secreted factors and EV-miRNAs: the example of joint disease

Abstract excerpt

BACKGROUND: Mesenchymal stromal cell (MSC)-enriched products showed positive clinical outcomes in regenerative medicine, where tissue restoration and inflammation control are needed. GMP-expanded MSCs displayed an even higher potential due to exclusive secretion of therapeutic factors, both free and conveyed within extracellular vesicles (EVs), collectively termed secretome. Moreover, priming with biochemical...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Extracellular vesicles in disease
• Share to Mesenchymal stem cell research
• Share to Osteoarthritis Treatment and Mechanisms